Changes in initial treatment for prostate cancer among medicare beneficiaries, 1999-2007

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 5, 2012, Pages

  Dinan, Michaela A ^a   Robinson, Timothy J ^a   Zagar, Timothy M ^b   Scales Jr , Charles D ^a,b   Curtis, Lesley H ^a,b   Reed, Shelby D ^a,b   Lee, W Robert ^b   Schulman, Kevin A ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen antagonists; Intensity modulated radiotherapy; Medicare; Physicians' practice patterns; Prostatectomy; Prostatic neoplasms

Indexed keywords

ANDROGEN ANTAGONISTS; INTENSITY-MODULATED RADIOTHERAPY; MEDICARE; PHYSICIANS' PRACTICE PATTERNS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

HEALTH CARE; HEALTH INSURANCE; PHYSICAL THERAPY; RADIOTHERAPY; SURGERY; THREE DIMENSIONAL; UROLOGY;

DISEASES;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MINIMALLY INVASIVE SURGERY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; THREE DIMENSIONAL CONFORMAL RADIATION THERAPY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; HUMANS; INCIDENCE; MALE; MEDICARE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84862798443     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.11.024     Document Type: Article

References (20)

1. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148:435-448. (Pubitemid 351665443)
2. Krupski TL, Kwan L, Afifi AA, et al. Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol 2005;23: 7881-7888. (Pubitemid 46657386)
3. Furlow B. US urology clinics overprescribe prostate radiotherapy. Lancet Oncol 2011;12:112.
4. Roehrig C, Miller G, Lake C, et al. National health spending by medical condition, 1996-2005. Health Aff (Millwood) 2009;28:w358-w367.
5. Hu JC,Wang Q, Pashos CL, et al. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol 2008;26:2278-2284.
6. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 2011;29:1517-1524.
7. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEERMedicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(8 Suppl): IV-3-18.
8. Hu JC, Hevelone ND, Ferreira MD, et al. Patterns of care for radical prostatectomy in the United States from 2003 to 2005. J Urol 2008; 180:1969-1974.
9. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA 2010;303:1625-1631.
10. Shea AM, Curtis LH, Hammill BG, et al. Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy. JAMA 2008;300:189-196. (Pubitemid 351969303)
11. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 2010; 363:1822-1832.
12. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009;302: 1202-1209.
13. Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 2007;25:3603-3608. (Pubitemid 47372597)
14. Bolenz C, Gupta A, Hotze T, et al. Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. Eur Urol 2010;57:453-458.
15. Barbash GI, Glied SA. New technology and health care costs: The case of robot-assisted surgery. N Engl J Med 2010;363:701-704.
16. Konski A, Watkins-Bruner D, Feigenberg S, et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 2006;66:408-415. (Pubitemid 44332736)
17. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. Lancet Oncol 2011;12:127-136.
18. Terakedis BE, Rossi PJ, Liauw SL, et al. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age. Am J Clin Oncol 2010;33:619-623.
19. Daskivich TJ, Chamie K, Kwan L, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2011; 117:2058-2066.
20. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-954. (Pubitemid 23244733)